Thanks for your interest in my syndicate. Please allow me to introduce the strategy behind my angel investments, share some of the methods used to select them and highlight the results they have achieved.

My angel investment strategy is simple: find great early stage companies with clear, upside exit potential and invest in them once or twice. Such companies usually have proven teams, operate in ascendant markets, have well-defined (and often well-protected) advantages over their competition and enjoy measurable traction in the marketplace.

Each of my investments is evaluated using a proprietary scoring system refined since 2007. The system analyzes various investment criteria across several key categories related to early stage investing. It then produces a series of scores which are useful for evaluating investment prospects as stand-alone opportunities or alongside other current or historical opportunities.

11 of my 45 investments across 35 companies have exited (including four IPO and seven acquisition investments), 24 continue to operate and 10 have wound down. This represents an 11% IPO rate, 24% exit rate and 53% still operating rate, several at robust step-up valuations with acquisition or IPO exits anticipated.

Co-investors of mine:

8VC
Asset Management Ventures/AMV
Andreesen Horowitz/a16z
ARCH Venture Partners
Data Collective/DCVC
EPIC Ventures
Foresite Capital
Google Ventures/GV
Illumina Ventures
Innovation Endeavors
Siemens Venture Capital
Softbank
Y Combinator

Exits of mine:

Avery Digital Data - Acquired by Federov
Conversa Health - Acquired by Amwell
Dogster - Acquired by Say Media
Genome Compiler - Acquired by Twist Bioscience
MD Insider - Acquired by Accolade
ONtheGO Platforms - Acquired by Atheer
Shout Interactive - Acquired by Eyematic Interfaces (also Co-Founder)
Twist Bioscience - IPO on Nasdaq
Zephyrus Biosciences - Acquired by Bio-techne
Zymergen - IPO on Nasdaq

Many of my investments have received significant follow-on rounds since I invested, including Circle Pharma, MycoWorks and Primordial Genetics → Primrose Bio. Other investments are receiving or positioned to receive significant follow-on rounds.

Joining my syndicate lets you invest alongside me. My recent investment focus has been on artificial intelligence and biotechnology companies. This is where my access, expertise and interests are strongest. I look forward to investing with you sometime soon!

Invest with Eric Anschutz

$129.5k

1

17

Team

Investments